The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Neutropenia Biologic Drug Treatment Market By 2030?
The neutropenia biologic drug treatment market size has shown substantial growth in recent years. This market is anticipated to expand from $14.78 billion in 2025 to $15.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical growth of this market can be attributed to several factors including an increase in cancer chemotherapy usage, the approval of filgrastim-based therapies, a rise in infection-related hospitalizations, the wider adoption of supportive oncology care, and the standardization of hospital protocols.
The neutropenia biologic drug treatment market is poised for significant expansion in the coming years. Its value is projected to reach **$20.88 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%.** This anticipated growth during the forecast period is primarily driven by factors such as a growing oncology patient population, increased penetration of biosimilars, a rising demand for long-acting formulations, the expansion of outpatient cancer care services, and an increase in healthcare expenditure. Key trends expected over this period involve a greater utilization of G-CSF biologics, the increasing adoption of long-acting biologic therapies, advancements in chemotherapy-induced neutropenia management, a strategic emphasis on biosimilars for cost reduction, and the broader distribution through hospitals and oncology pharmacies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp
What Primary Factors Are Fueling The Expansion Of The Neutropenia Biologic Drug Treatment Market?
The global increase in cancer occurrences is projected to stimulate the expansion of the market for neutropenia biologic drugs. A rising incidence of cancer, coupled with more individuals undergoing chemotherapy, has led to a greater number of people developing neutropenia. For instance, data from July 2024 by the Australian Institute of Health and Welfare, an Australia-based government entity, indicated that in 2023, approximately 165,000 Australians received a new cancer diagnosis, which amounts to over 450 cases daily, with males accounting for roughly 55% of these diagnoses. Consequently, the escalating global cancer incidence rates are expected to boost the demand for neutropenia biologic drug treatment in the coming years.
How Is The Neutropenia Biologic Drug Treatment Market Examined Through Segment Analysis?
The neutropenia biologic drug treatment market covered in this report is segmented –
1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim
2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Which Trends Are Supporting The Evolution Of The Neutropenia Biologic Drug Treatment Market?
Leading companies involved in neutropenia biologic drug treatment are developing biosimilars to provide more economical alternatives to currently available biologics. Biosimilars are biologic medicines crafted to be nearly identical to an already approved reference biologic, showing no notable discrepancies in safety or effectiveness. For example, in May 2023, Amneal Pharmaceuticals, a pharmaceutical company from the US, introduced Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, designed to treat and prevent febrile neutropenia in patients undergoing chemotherapy. It operates by binding to specific receptors on hematopoietic cells, thereby stimulating the multiplication and differentiation of neutrophil precursors within the bone marrow. This process enhances the generation of neutrophils, which are essential for combating infections, especially in individuals undergoing myelosuppressive chemotherapy, thus decreasing the occurrence of febrile neutropenia connected with cancer treatments.
Who Are The Leading Firms Participating In The Neutropenia Biologic Drug Treatment Market?
Major companies operating in the neutropenia biologic drug treatment market are Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy’s Laboratories Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.
Access The Complete Neutropenia Biologic Drug Treatment Market Report:
Which Region Leads The Neutropenia Biologic Drug Treatment Market By Size?
North America was the largest region in the neutropenia biologic drug treatment market in 2025. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Neutropenia Biologic Drug Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp
Browse Through More Reports Similar to the Global Neutropenia Biologic Drug Treatment Market 2026, By The Business Research Company
Oncology Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Pegfilgrastim Biosimilars Market 2026
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilars-market
Orthopedic Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/orthopedic-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model